ePrints

Scaling up human mesenchymal stem cell manufacturing using bioreactors for clinical uses

Lookup NU author(s): Dr Sanja Bojic

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2023 Elsevier Masson SASHuman mesenchymal stem cells (hMSCs) are multipotent cells and an attractive therapeutic agent in regenerative medicine and intensive clinical research. Despite the great potential, the limitation that needs to be overcome is the necessity of ex vivo expansion because of insufficient number of hMSCs presented within adult organs and the high doses required for a transplantation. As a result, numerous research studies aim to provide novel expansion methods in order to achieve appropriate numbers of cells with preserved therapeutic quality. Bioreactor-based cell expansion provide high-level production of hMSCs in accordance with good manufacturing practice (GMP) and quality standards. This review summarizes current knowledge about the hMSCs manufacturing platforms with a main focus to the application of bioreactors for large-scale production of GMP-grade hMSCs.

Publication metadata

Author(s): Jankovic MG, Stojkovic M, Bojic S, Jovicic N, Kovacevic MM, Ivosevic Z, Juskovic A, Kovacevic V, Ljujic B

Publication type: Review

Publication status: Published

Journal: Current Research in Translational Medicine

Year: 2023

Volume: 71

Issue: 2

Print publication date: 01/04/2023

Online publication date: 28/04/2023

Acceptance date: 26/04/2023

ISSN (electronic): 2452-3186

Publisher: Elsevier Masson s.r.l.

URL: https://doi.org/10.1016/j.retram.2023.103393

DOI: 10.1016/j.retram.2023.103393

Share